CD8A and neoplasm: The combined use of cyclophosphamide (CTX) and an agonist antibody targeting the OX86 could enhance antitumor immunity and was capable of regressing established B16 melanoma tumors by inducing tumor-infiltrating Treg cell apoptosis and favorably increasing the intratumoral CD8+T cell/Treg cell ratio [197].